Literature DB >> 27818912

Evaluating and Managing Sleep Disorders in the Parkinson's Disease Clinic.

S Gulyani1, R Salas2, Z Mari2, S Choi2, A Mahajan3, C Gamaldo2.   

Abstract

Parkinson's disease is a multi-systems neurodegenerative disorder that is characterized by a combination of motor and non-motor symptoms. Non-motor symptoms of Parkinson's disease comprise a variety of cognitive, neuropsychiatric, autonomic, sensory, and sleep complaints. Although sleep disruption represents one of the most common non-motor symptom complaints among Parkinson's disease patients, recommendations regarding effective evaluation and management strategies for this specific population remain limited. This review gives an evidence based summary of the available treatment options and management strategies for the sleep complaints commonly encountered by patients with Parkinson's disease.

Entities:  

Year:  2016        PMID: 27818912      PMCID: PMC5089171          DOI: 10.1016/j.baga.2016.05.001

Source DB:  PubMed          Journal:  Basal Ganglia        ISSN: 2210-5336


  77 in total

1.  Increased risk of leg motor restlessness but not RLS in early Parkinson disease.

Authors:  M D Gjerstad; O B Tysnes; J P Larsen
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

Review 2.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

3.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

4.  Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.

Authors:  A L Leeman; C J O'Neill; P W Nicholson; A A Deshmukh; M J Denham; J P Royston; R J Dobbs; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

5.  Gait and attentional performance in freezers under methylphenidate.

Authors:  A Delval; C Moreau; S Bleuse; D Guehl; E Bestaven; E Guillaud; K Dujardin; L Defebvre; D Devos
Journal:  Gait Posture       Date:  2014-10-30       Impact factor: 2.840

6.  Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.

Authors:  Donald L Bliwise; Lynn Marie Trotti; Anthony G Wilson; Sophia A Greer; Cathy Wood-Siverio; Jorge J Juncos; Stewart A Factor; Alan Freeman; David B Rye
Journal:  Mov Disord       Date:  2012-07-02       Impact factor: 10.338

7.  Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

Authors:  William G Ondo; Thomas Perkins; Todd Swick; Keith L Hull; J Ernesto Jimenez; Tippy S Garris; Daniel Pardi
Journal:  Arch Neurol       Date:  2008-10

8.  Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology.

Authors:  Sean J Pittock; Timothy Parrett; Charles H Adler; Joseph E Parisi; Dennis W Dickson; J Eric Ahlskog
Journal:  Mov Disord       Date:  2004-06       Impact factor: 10.338

9.  Treatment outcomes in REM sleep behavior disorder.

Authors:  Stuart J McCarter; Christopher L Boswell; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Bradley F Boeve; Michael H Silber; Eric J Olson; Maja Tippmann-Peikert
Journal:  Sleep Med       Date:  2013-01-23       Impact factor: 3.492

10.  Factors contributing to the development of restless legs syndrome in patients with Parkinson disease.

Authors:  Ji E Lee; Hae-Won Shin; Kyung S Kim; Young H Sohn
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

View more
  1 in total

1.  Does restless legs syndrome impact cognitive function via sleep quality in adults with Parkinson's disease?

Authors:  Katie L Cederberg; Elizabeth B Brinkley; Natalya Belotserkovkaya; Raima A Memon; Robert W Motl; Amy W Amara
Journal:  Int J Neurosci       Date:  2019-10-25       Impact factor: 2.292

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.